No Data
No Data
Selected announcements | CNPC's net profit last year exceeded 160 billion yuan; Pharmaceutical Federation's annual profit increased by more than 80% year-on-year
China Overseas Hongyang Group: Net profit of 2023 was 2.02 billion yuan, down 26.94% year on year; Zero Sports Auto: 2023 revenue of 16.747 billion yuan, up 35.22% year on year; Tencent Holdings: spent HK$1,001 billion to buy back 3.47 million shares on March 25.
Guichuang Tongqiao (02190.HK): Intensive launch of a variety of new products drives performance growth and further increases market share in collection and release
Incident: The company announced its 2023 annual results, achieving operating income of 528 million yuan (+58.0%), net profit to mother of 7.873 million yuan (+30.7%), deducting 7.033 million yuan (+1) from non-return mother
Guichuang Tongqiao-B (02190.HK): The State Drug Administration approved the launch of the Tongqiao Kirin blood flow guide device
On March 25, Gelonghui | Guichuang Tongqiao-B (02190.HK) announced that the Tongqiao Kirin blood flow guidance device independently developed by the Group has been approved for listing by the China Drug Administration (“State Drug Administration”). As the first fully developed remote closed dense mesh stent made in China, the Tsuqiao Kirin blood flow guide device will not only bring new treatment options for intracranial aneurysm treatment; at the same time, it will further enrich the company's product portfolio matrix and enhance the company's influence in the field of neurovascular interventional treatment in China. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 41 products in China. According to the disclosure, blood
Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023
Zylox-Tonbridge Medical Technology (HKG:2190) recorded a 30.7% decline in attributable loss for the year ended Dec. 31, 2023, to 78.7 million yuan from 113.6 million yuan in 2022, a Friday filing on t
Press Release: Zylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability
HANGZHOU, China, March 22, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023.
Guichuang Tongqiao-B (02190.HK): Performance is in line with expectations, domestic alternatives continue to be verified
The 2023 results are in line with our expectations: revenue of $528 million, +58% year over year; adjusted net profit of 7.03 million yuan (adjusted loss of 25.88 million yuan in 2022). revenues
No Data